Valsartan, a new angiotensin II antagonist: Antihypertensive effects over 24 hours

Clinical Therapeutics

Volumn 19, Issue 3, 1997, Pages 447-458

  Neutel, Joel ^a   Weber, Michael ^b   Pool, James ^c   Smith, David ^a   Fitzsimmons, Sheila ^d   Chiang, Yann Tong ^d   Gatlin, Majorie ^d  

^a Orange County Heart Institute and Research Center   (United States)

^b Memorial Research Medical Clinic   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Ambulatory blood pressure monitoring; Essential hypertension; Valsartan

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; PLACEBO; VALSARTAN;

ADULT; AGED; AMBULATORY MONITORING; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTPATIENT; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

EID: 0030814394     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80129-4     Document Type: Article

References (22)

1. Kannel WB. The role of blood pressure in cardiovascular morbidity and mortality. Prog Cardiovasc Dis. 1976;17:5-23.
2. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary heart disease. Part 2. Short-term reductions in blood pressure: Overview of randomized drug trials in their epidemiological context. Lancet. 1990;335:827-838.
3. Kaplan NM. Clinical Hypertension. 6th ed. Baltimore, Md: Williams & Wilkins; 1994.
4. Neutel JM, Smith DH, Ram CV, et al. Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. Am J Med. 1993;94: 181-187.
5. Coats AJS, Radaelli A, Clark SJ, et al. The influence of ambulatory blood pressure monitoring on the design and interpretation of trials in hypertension. J Hypertens. 1992;10:385-391.
6. Criscione L, de Gasparo M, Bühlmayer P, et al. Pharmacological profile of valsartan: A potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol. 1993; 110:761-771.
7. Müller P, Cohen T, de Gasparo M, et al. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol. 1994;47:231-245.
8. Criscione L, Bradley WA, Bühlmayer P, et al. Valsartan: Preclinical and clinical profile of an antihypertensive angiotensin-II antagonist. Cardiovasc Drug Rev. 1995; 13:230-250.
9. Foote EF, Halstenson CE. New therapeutic agents in the management of hypertension: Angiotensin II receptor antagonists and renin inhibitors. Ann Pharmacother. 1993;27:1495-1503.
10. Oparil S, Dyke S, Harris F, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther. 1996;18:797-810.
11. Holwerda NJ, Fogari R, Angeli P, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy and safety compared to placebo and enalapril. J Hypertens. 1996; 14:1147-1151.
12. Corea L, Cardoni O, Fogari R, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther. 1996;60:341-346.
13. Benz J, Oshrain C, Henry D, et al. Valsartan, a new angiotensin II receptor antagonist: A double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol. 1997;37:101-107.
14. Hegner G, Faust G, Freytag F, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy and safety compared to hydrochlorothiazide. Eur J Pharmacol. 1997;52:173-177.
15. Neutel JM, Schnaper H, Cheung DG, et al. Antihypertensive effects of β-blockers administered once daily: 24-Hour measurements. Am Heart J. 1990;120:166-171.
16. Muller JE, Stone PH, Turi ZG. Circadian variation in the frequency of onset of acute myocardial infarction. NEJM. 1985;313: 1315-1322.
17. Tofler GH, Brezinski D, Schafer AI. Concurrent morning increase in platelet aggregability and risk of myocardial infarction and sudden cardiac death. NEJM. 1987;316:1514-1518.
18. Maries JR, Price TR, Clark GL. Morning increase in onset of ischemic stroke. Stroke. 1989;20:473-476.
19. Rocco MB, Barry J, Cambell S. Circadian variation of transient myocardial ischemia in patients with coronary artery disease. Circulation. 1987;75:395-400.
20. Deedwania PC, Nelson JR. Pathophysiology of silent myocardial ischemia during daily life. Hemodynamic evaluation by simultaneous electrocardiographic and blood pressure monitoring. Circulation. 1990;82:1296-1304.
21. Tallant EA, Ferrario CM. Biology of angiotensin II receptor inhibition with a focus on losartan: A new drug for the treatment of hypertension. Exp Opin Invest Drugs. 1996;5:1201-1214.
22. Zannad F. Duration of action of angiotensin converting enzyme inhibitors. Am J Hypertens. 1995;8:75S-81S.